CSIMarket
 
Cellectar Biosciences inc   (CLRB)
Other Ticker:  
 

Cellectar Biosciences inc

Business Description


Cellectar Biosciences Inc. is a biopharmaceutical company founded in 2003 and headquartered in Madison, Wisconsin. The company is focused on the development of targeted therapeutic drugs for the treatment of various types of cancer, with a specific emphasis on rare and difficult-to-treat forms of the disease.

Cellectar Biosciences* core technology, known as phospholipid drug conjugates (PDCs), combines the benefits of small-molecule drugs with the targeted delivery characteristics of phospholipid ethers. PDCs allow for the selective targeting and retention of the conjugated drugs within tumor cells, leading to increased efficacy and reduced systemic toxicity.

The company*s lead product candidate is CLR 131, which is in advanced clinical trials for the treatment of multiple myeloma, a type of blood cancer. CLR 131 is a radiotherapeutic PDC that delivers a radioactive isotope directly to tumor cells, causing localized radiation damage to cancerous cells while sparing normal healthy tissues. The drug has shown promise in preclinical and early-stage clinical studies, with encouraging results indicating its potential as a targeted therapy for multiple myeloma and other malignancies.

Cellectar Biosciences also has a pipeline of other PDC compounds in preclinical and early clinical development, targeting a range of cancer types, including lymphomas, solid tumors, and pediatric malignancies. These include CLR 125, CLR 124, and CLR 1502, among others.

In addition to its therapeutic pipeline, Cellectar Biosciences has developed CLR 1800, a diagnostic PDC, for the detection of certain cancers using Positron Emission Tomography (PET) imaging. CLR 1800 is designed to selectively bind to cancer cells, allowing for improved visualization and identification of tumor sites. This diagnostic technology has the potential to aid in cancer diagnosis and staging, as well as monitoring the response to treatment.

Cellectar Biosciences has established collaborations and partnerships with several academic institutions, research organizations, and pharmaceutical companies to advance its drug development programs. These collaborations aim to leverage the expertise and resources of various partners to accelerate research and development efforts, enhance clinical trial design, and expand the therapeutic applications of its PDC platform technology.

The company operates in a highly competitive and regulated biopharmaceutical industry. It faces challenges in terms of securing funding for research and development, obtaining regulatory approvals for its drug candidates, and navigating the complex process of clinical trials. However, Cellectar Biosciences* innovative PDC technology, combined with an experienced management team and a strong scientific network, positions the company for continued growth and potential breakthroughs in the field of targeted cancer therapeutics.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com